科济药业-B今日盘中股价大涨6.2%,引起市场广泛关注。这一异动或与该公司创新疗法的良好前景有关。
作为一家专注于CAR-T细胞疗法研发的生物制药公司,科济药业目前正在推进其核心产品CT053的临床试验。CT053是针对多发性骨髓瘤的BCMA靶向CAR-T细胞疗法,预计将有望填补该疾病治疗的空白。
公司的CAR-T技术平台不仅用于血液肿瘤,同时也覆盖实体瘤领域。若后续研发取得重大进展,将有望提升公司的长期增长空间,这可能是导致其股价今日大涨的主要因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.